SpyGlass Pharma Common Stock Receivables

SpyGlass Pharma Common Stock's receivables stands at $680K as of June 2026. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Open the history chart to see whether SpyGlass Pharma Common Stock's receivables is expanding or contracting. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how SpyGlass Pharma Common Stock's receivables evolved across reporting periods, while the comparison chart places SGP next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, receivables is commonly used to spot outliers. SpyGlass Pharma Common Stock's reading of $680K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.